Special Issue "Cancer Associated Coagulation"

A special issue of Hemato (ISSN 2673-6357). This special issue belongs to the section "Coagulation".

Deadline for manuscript submissions: closed (30 April 2021).

Special Issue Editor

Dr. Leigh A. Madden
E-Mail Website
Guest Editor
Department of Biomedical Science, The University of Hull, Hull HU6 7RX, UK
Interests: extracellular vesicles and coagulation; cancer-associated coagulation; endothelial function; translational chemistry

Special Issue Information

Dear Colleagues,

This Special Issue aims to encompass research in all aspects of cancer-associated coagulation, from understanding the mechanisms of tumour-driven hypercoagulopathy to advances in anticoagulant treatment and patient management. Certain tumours, such as those of the pancreas and ovaries, are associated with an increased risk of the patient developing venous thromboembolism and this risk increases further with chemotherapy by mechanisms currently being investigated. Patients are managed with the use of anticoagulants such as low-molecular-weight heparin or orally administered alternatives. Of particular interest is the role of extracellular vesicles within these processes and also research investigating the impact of COVID-19, although studies on all aspects of cancer-associated coagulation are welcome.

Dr. Leigh A. Madden
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hypercoagulopathy
  • extracellular vesicles
  • anticoagulants
  • chemotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Individualised Risk Assessments for Recurrent Venous Thromboembolism: New Frontiers in the Era of Direct Oral Anticoagulants
Hemato 2021, 2(1), 64-78; https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010003 - 15 Jan 2021
Viewed by 455
Abstract
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality and is associated with high recurrence rates. The introduction of direct oral anticoagulants (DOACs) in the 2010s has changed the landscape of VTE management. DOACs have become the preferred anticoagulant therapy for [...] Read more.
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality and is associated with high recurrence rates. The introduction of direct oral anticoagulants (DOACs) in the 2010s has changed the landscape of VTE management. DOACs have become the preferred anticoagulant therapy for their ease of use, predictable pharmacokinetics, and improved safety profile. Increasingly, guidelines have recommended long term anticoagulation for some indications such as following first unprovoked major VTE, although an objective individualised risk assessment for VTE recurrence remains elusive. The balance of preventing VTE recurrence needs to be weighed against the not insignificant bleeding risk, which is cumulative with prolonged use. Hence, there is a need for an individualised, targeted approach for assessing the risk of VTE recurrence, especially in those patients in whom the balance between benefit and risk of long-term anticoagulation is not clear. Clinical factors alone do not provide the level of discrimination required on an individual level. Laboratory data from global coagulation assays and biomarkers may provide enhanced risk assessment ability and are an active area of research. A review of the prediction models and biomarkers for assessing VTE recurrence risk is provided, with an emphasis on contemporary developments in the era of DOACs and global coagulation assays. Full article
(This article belongs to the Special Issue Cancer Associated Coagulation)
Back to TopTop